Kyverna Therapeutics News

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 70.4% to $3.51 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. Molecular Partners (NASDA

BenzingaJun 3 20:07

Buy Rating for Kyverna Therapeutics Based on KYV-101's Clinical Progress and Financial Stability

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report), with a price target of $44.00.

TipRanksMay 16 17:45

Kyverna Therapeutics | 10-Q: Quarterly report

SEC announcementMay 15 04:35 · Announcements

Kyverna Therapeutics Q1 2024 Adj EPS $(1.12) Misses $(0.84) Estimate

Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.12) per share which missed the analyst consensus estimate of $(0.84) by 33.33 percent.

BenzingaMay 15 04:34

Press Release: Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results PR Newswire EMERYVILLE, Calif., May 14, 2024 -- Advanced clinical development in two broad areas of

Dow JonesMay 15 04:05

8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard

Seeking AlphaMay 12 23:22

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it

BenzingaApr 30 01:04

Buy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Drug Efficacy and Safety Data

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report), with a price target of $44.00.

TipRanksApr 17 17:05

Buy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Clinical Advances

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report), retaining the price target of $40.00.

TipRanksApr 17 01:25

Kyverna Therapeutics to Attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients With Neurological Autoimmune Diseases

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...

PR NewswireApr 12 05:01

12 Health Care Stocks Moving In Monday's After-Market Session

GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in

BenzingaApr 2 04:31

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The trea

PR NewswireMar 30 02:59

Buy Recommendation: Kyverna Therapeutics' Innovative Autoimmune Cell Therapy and Robust Pipeline Promise Market Leadership

TipRanksMar 29 15:06

Buy Rating Affirmed on Kyverna Therapeutics Amid Anticipated Clinical Updates and Strong Financial Position

TipRanksMar 27 16:55

Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY

Financial Results for the Year Ended December 31, 2023For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a ne

BenzingaMar 27 04:20

Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX

Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX

Dow JonesMar 27 04:06

Press Release: Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results PR Newswire EMERYVILLE, Calif., March 26, 2024 -- Advanced clinical development in two broad areas of a

Dow JonesMar 27 04:05

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Health care stocks were steady pre-bell Friday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% recently. Amylyx Pharmaceutica

MT NewswiresMar 8 22:17

Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participantsThe clinical study wil

BenzingaMar 8 15:20

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients With Non-Relapsing and Progressive Forms of Multiple Sclerosis

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients...

PR NewswireMar 8 08:26